Prostatic Neoplasms — MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
Citation(s)
A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease